Profil bibliographique

Sanjiv S. Agarwala

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

306Publications signalées

28438Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

Cutaneous Melanoma Detection and ManagementCAR-T cell therapy researchMelanoma and MAPK PathwaysCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Publications récentes

2026 conference-abstractOpenAlex

Final results and correlative analysis of entinostat (E) plus pembrolizumab (P) in patients (Pts) with metastatic melanoma (MM) previously treated with anti–PD-(L)1 therapy (Tx).

Stergios Moschos, Meghan J. Mooradian, Melissa L. Johnson, Mateusz Opyrchal et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2025 articleOpenAlex

Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma

Ryan J. Sullivan, Katy K. Tsai, Anna C. Pavlick, Elizabeth I. Buchbinder et autres

2 citationsJournal of Cancer

2025 articleOpenAlex

Accuracy and Reproducibility of ChatGPT Responses to Breast Cancer Tumor Board Patients

Ning Liao, Cheukfai Li, William J. Gradishar, V. Suzanne Klimberg et autres

6 citationsJCO Clinical Cancer Informatics

Accès ouvert 2024 articleOpenAlex

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra, Barbara Burtness et autres

240 citationsThe Lancet Oncology

Accès ouvert 2024 preprintOpenAlex

Accuracy and Reproducibility of ChatGPT Responses to 362 Breast Cancer Tumor Board Cases

Ning Liao, Cheukfai Li, William J. Gradishar, V. Suzanne Klimberg et autres

4 citationsSSRN Electronic Journal

2023 articleOpenAlex

Systemic Therapy for Melanoma: ASCO Guideline Update Q and A

Vernon K. Sondak, Michael B. Atkins, Hans Messersmith, Anthony Provenzano et autres

18 citationsJCO Oncology Practice

Accès ouvert 2023 articleOpenAlex

Systemic Therapy for Melanoma: ASCO Guideline Update

Rahul Seth, Sanjiv S. Agarwala, Hans Messersmith, Krishna Alluri et autres

218 citationsJournal of Clinical Oncology

Accès ouvert 2023 articleOpenAlex

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st–3rd, 2022—Naples, Italy)

Paolo A. Ascierto, Sanjiv S. Agarwala, Allison Betof Warner, Marc S. Ernstoff et autres

5 citationsJournal of Translational Medicine

Accès ouvert 2023 articleOpenAlex

Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma

Drew Rasco, Theresa Medina, Pippa Corrie, Anna C. Pavlick et autres

44 citationsCancer Chemotherapy and Pharmacology

Accès ouvert 2023 supplementary-materialsOpenAlex

Supplementary Data from Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)

Hani M. Babiker, Erkut Borazanci, Vivek Subbiah, Sanjiv S. Agarwala et autres

0 citations

Accès ouvert 2023 supplementary-materialsOpenAlex

Supplementary Data from Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)

Hani M. Babiker, Erkut Borazanci, Vivek Subbiah, Sanjiv S. Agarwala et autres

0 citations

Accès ouvert 2023 otherOpenAlex

Data from Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)

Hani M. Babiker, Erkut Borazanci, Vivek Subbiah, Sanjiv S. Agarwala et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.